Wegovy vs. Mounjaro: Cost Comparison and Coverage Analysis for GLP-1 Users
Choosing between Wegovy and Mounjaro isn't just a clinical decision — it's a financial one. Both GLP-1 medications carry steep list prices that can easily exceed $1,000 per month without insurance. This comparison breaks down real costs, insurance coverage realities, and savings strategies to help you make an informed choice.
Understanding the List Prices: What You'd Pay Without Insurance
Before diving into coverage details, it helps to understand what these medications actually cost at the pharmacy counter when no insurance is involved. These numbers set the baseline for every savings strategy discussed below.
Wegovy's Current List Price
Wegovy (semaglutide), manufactured by Novo Nordisk, carries a list price of approximately $1,349 per month as of 2024. That figure is for a single monthly supply at the maintenance dose. Because Wegovy's dosing is titrated upward over several months, patients starting treatment will move through multiple dose levels — each with its own pricing tier — before reaching the standard 2.4 mg maintenance dose. Over a full year, list-price costs can approach or exceed $16,000 for patients without meaningful coverage.
Mounjaro's Current List Price
Mounjaro (tirzepatide), made by Eli Lilly, has a list price hovering around $1,069 to $1,200 per month depending on the dose. Mounjaro is technically approved by the FDA for type 2 diabetes management, not obesity — a distinction that carries enormous coverage implications discussed later. Its dual GIP/GLP-1 receptor agonist mechanism has made it clinically popular, but the monthly cost still places it firmly in premium territory for uninsured patients.
Want to see exactly what you'd pay based on your specific dose and insurance situation? Use the GLP-1 cost calculator to get a personalized estimate in minutes.
Insurance Coverage: The Single Biggest Cost Variable
The gap between list price and what patients actually pay at the pharmacy is almost entirely determined by insurance coverage. And here's where Wegovy and Mounjaro diverge sharply — not just in dollar amounts, but in the logic insurers use to decide coverage at all.
How Wegovy Fares with Commercial Insurance
Wegovy received FDA approval specifically for chronic weight management in adults with obesity or weight-related conditions. That approval pathway matters because many commercial insurance plans categorize it as a weight loss drug — a category that has historically faced significant coverage exclusions. According to data tracked by health policy researchers, fewer than half of commercial plans covered GLP-1 medications for weight management as recently as 2023, though that number has been shifting as employer benefit plans respond to employee demand.
When Wegovy is covered, typical commercial insurance copays range from $25 to $150 per month, though prior authorization requirements are nearly universal. Insurers frequently require documented BMI thresholds (usually 30+, or 27+ with a qualifying comorbidity), a history of failed lifestyle interventions, and sometimes a prescriber letter of medical necessity.
How Mounjaro Fares with Commercial Insurance
Mounjaro's situation is more nuanced. Because it is FDA-approved for type 2 diabetes, patients with a diabetes diagnosis often find it much easier to get covered — insurers routinely cover diabetes medications, and Mounjaro fits cleanly into that category. For a patient using Mounjaro to manage blood sugar, commercial coverage is relatively common, with copays often landing in the $25 to $100 range after deductible.
However, for patients seeking Mounjaro primarily for weight loss without a diabetes diagnosis, coverage becomes a different story. Some plans still deny it or require the same burdensome prior authorization process applied to Wegovy. This creates an uneven landscape where two patients on identical doses of the same drug can have completely different out-of-pocket experiences based solely on their diagnosis codes.
Medicare and Medicaid Coverage Realities
Federal insurance programs introduce another layer of complexity — and for many GLP-1 users, this is where costs become most unpredictable.
Medicare Coverage of Wegovy and Mounjaro
Medicare has historically been prohibited from covering weight loss medications under Part D, stemming from statutory exclusions written long before drugs like Wegovy existed. However, the Inflation Reduction Act and subsequent CMS guidance have begun shifting this landscape. As of early 2024, CMS issued guidance allowing Medicare to cover semaglutide (Wegovy) when prescribed for cardiovascular risk reduction — specifically following the SELECT trial results showing reduced cardiovascular events in patients with obesity and established heart disease.
You can review CMS's official coverage guidance directly at cms.gov for the most current Medicare drug coverage policies affecting GLP-1 medications.
For Mounjaro, Medicare Part D coverage is more established for diabetes-diagnosed beneficiaries, since it falls under diabetic drug coverage. Medicare patients without diabetes face similar exclusion barriers as commercial insurance patients seeking Mounjaro for weight management alone.
Medicaid Coverage Variability
Medicaid coverage for both drugs varies dramatically by state, since states have significant discretion in their Medicaid formularies. Some state Medicaid programs cover Mounjaro for diabetes management with minimal barriers, while others have placed high prior authorization hurdles or excluded GLP-1s entirely from weight management coverage. Wegovy's Medicaid coverage for obesity treatment remains limited across most states. Patients relying on Medicaid should contact their state program or pharmacist directly, as national generalizations are difficult to apply accurately here.
Manufacturer Savings Programs: Bridging the Coverage Gap
Both Novo Nordisk and Eli Lilly have created savings programs that can dramatically reduce costs for commercially insured and even uninsured patients — but each program has its own eligibility rules and limitations.
Novo Nordisk's Wegovy Savings Offer
Novo Nordisk offers a savings card program for commercially insured Wegovy patients, with some patients reporting out-of-pocket costs as low as $0 to $25 per month for the first year or a defined number of fills. Eligibility typically excludes Medicare, Medicaid, and other government-funded insurance recipients — a crucial limitation given how many GLP-1 users are on federal programs. Income-based assistance programs exist separately for patients who meet financial need criteria.
Eli Lilly's Mounjaro Savings Card
Eli Lilly has similarly offered a savings card for Mounjaro, with promotional periods where eligible commercially insured patients paid as little as $25 per fill. Like Wegovy's program, these savings are unavailable to Medicare and Medicaid beneficiaries due to federal anti-kickback statutes. It's worth noting that these savings programs change frequently — what was true in 2023 may not reflect 2024 or 2025 terms — so verifying current offers directly with the manufacturer before making cost assumptions is essential.
For a side-by-side breakdown of how these savings programs affect your total annual cost, the GLP-1 cost calculator factors in available discounts to show realistic net costs.
Compounded Versions: The Cost-Cutting Wildcard
During periods of drug shortage, the FDA permitted compounding pharmacies to produce versions of semaglutide and tirzepatide at significantly lower price points — sometimes $200 to $500 per month compared to brand-name list prices. These compounded versions attracted enormous patient interest precisely because of the cost gap.
However, compounded GLP-1 medications carry regulatory uncertainty. The FDA has pushed back against compounding of these drugs as shortage designations have been lifted or contested, and the safety and potency of compounded versions are not subject to the same FDA review as brand-name products. Patients considering compounded options should understand both the potential cost savings and the regulatory and quality considerations involved before proceeding.
Frequently Asked Questions
Is Wegovy or Mounjaro cheaper after insurance?
It depends almost entirely on your specific insurance plan and your diagnosis. Patients with type 2 diabetes typically find Mounjaro more accessible through commercial insurance due to its diabetes approval. Patients seeking coverage for obesity treatment without a diabetes diagnosis may face similar hurdles with both drugs. With manufacturer savings cards applied, commercially insured patients can sometimes reach comparable out-of-pocket costs for both medications — as low as $25 per month. Always run your specific situation through a cost tool before assuming either drug is cheaper for you personally.
Does Medicare cover Wegovy or Mounjaro for weight loss?
Medicare coverage for weight loss purposes has been historically excluded by statute, though CMS guidance issued in 2024 opened a pathway for Wegovy coverage when prescribed for cardiovascular risk reduction in qualifying patients. Mounjaro has better Medicare coverage prospects for beneficiaries with a type 2 diabetes diagnosis under Part D. Medicare beneficiaries should review current CMS formulary guidance and contact their Part D plan directly to confirm current coverage status, as policies have been evolving rapidly.
What happens to my costs if my insurance doesn't cover GLP-1 medications?
Without insurance coverage, list prices for both Wegovy and Mounjaro exceed $1,000 per month, making long-term use financially unsustainable for most patients. Options include applying for manufacturer patient assistance programs (income-based), exploring whether a telehealth provider can prescribe through a platform with negotiated pricing, reviewing whether a diagnosis change affects coverage eligibility, or — with careful awareness of the caveats — exploring compounded alternatives during periods when they are legally available. A GLP-1 cost calculator can help map out total annual costs under different coverage scenarios so you can compare options clearly.
Can I switch from Mounjaro to Wegovy to get better coverage?
Switching medications purely for cost or coverage reasons should always involve your prescriber, since the two drugs work through slightly different mechanisms and have different clinical profiles. That said, some patients do switch between GLP-1 agents based on coverage changes — especially if a new employer benefit plan covers one drug but not the other. If you're considering a switch, bring your insurance formulary documentation to your appointment so the clinical and financial discussion can happen together.